» Articles » PMID: 37152037

Necroptosis-related LncRNAs: Establishment of a Gene Module and Distinction Between the Cold and Hot Tumors in Glioma

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 May 8
PMID 37152037
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gliomas are the most common primary tumors of the central nervous system and portend a poor prognosis. The efficacy of emerging and promising immunotherapies varies significantly among individuals. Distinction and transformation of cold and hot tumors may improve the antitumor efficacy of immunotherapy.

Methods And Results: In this study, we constructed a necroptosis-related lncRNA module based on public databases. The association of this module with survival was assessed using the Cox regression, Kaplan-Meier survival analysis, and nomogram, external validation was also conducted in another public database. Furthermore, we performed gene set enrichment analysis (GSEA), immune checkpoint and tumor microenvironment analysis, and qRT-PCR validation. Finally, we clustered all samples into 2 clusters based on the expression of model lncRNAs and identified cluster 1 as cold tumors with fewer infiltrating T cells.

Conclusions: Identifying cold and hot tumors by necroptosis-related lncRNAs can help available immunotherapeutic strategies to achieve efficacy in the precise treatment of individuals. Prior treatment failure can be overcome by targeting necroptosis-related lncRNAs.

Citing Articles

The fate and function of non-coding RNAs during necroptosis.

Bozgeyik E, Elek A, Gocer Z, Bozgeyik I Epigenomics. 2024; 16(11-12):901-915.

PMID: 38884366 PMC: 11370912. DOI: 10.1080/17501911.2024.2354653.


High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.

Wang H, Xie Y, Du H, Luo B, Li Z PeerJ. 2023; 11:e16104.

PMID: 37810780 PMC: 10557942. DOI: 10.7717/peerj.16104.


Necrotic related-lncRNAs: Prediction of prognosis and differentiation between cold and hot tumors in head and neck squamous cell carcinoma.

Shi Y, Zhang Y, Zuo N, Wang L, Sun X, Liang L Medicine (Baltimore). 2023; 102(23):e33994.

PMID: 37335630 PMC: 10256380. DOI: 10.1097/MD.0000000000033994.

References
1.
Das S, Camphausen K, Shankavaram U . Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. Cancers (Basel). 2020; 12(9). PMC: 7563367. DOI: 10.3390/cancers12092476. View

2.
Jiang F, Zhan Z, Yang Y, Liu G, Liu S, Gu J . Construction and Validation of a Necroptosis-Related lncRNA Signature in Prognosis and Immune Microenvironment for Glioma. J Oncol. 2022; 2022:5681206. PMC: 9440826. DOI: 10.1155/2022/5681206. View

3.
Li Z, Feng C, Guo J, Hu X, Xie D . GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization. Funct Integr Genomics. 2019; 20(1):17-28. DOI: 10.1007/s10142-019-00696-x. View

4.
Chen D, Dou C, Liu H, Xu B, Hu B, Kuang L . Comprehensive analysis: Necroptosis-related lncRNAs can effectively predict the prognosis of glioma patients. Front Oncol. 2022; 12:929233. PMC: 9402092. DOI: 10.3389/fonc.2022.929233. View

5.
Ostrom Q, Bauchet L, Davis F, Deltour I, Fisher J, Langer C . The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7):896-913. PMC: 4057143. DOI: 10.1093/neuonc/nou087. View